Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fingolimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 known ✓ | P21453 | 11/20 | 1.00 |
| ▸ | S1PR3 known ✓ | Q99500 | 9/20 | 0.97 |
| ▸ | S1PR4 known ✓ | O95977 | 7/20 | 0.97 |
| ▸ | S1PR5 known ✓ | Q9H228 | 5/20 | 0.97 |
| ▸ | S1PR2 known ✓ | O95136 | 5/20 | 0.72 |
| ▸ | TNNC1 | P63316 | 6/20 | 0.97 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.97 |
| ▸ | GPR183 | P32249 | 1/20 | 0.97 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.97 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.76 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.76 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6260676 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| Hydrochloric Acid SCHEMBL8498778 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| Hydrochloric Acid SCHEMBL8500527 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| Hydrochloric Acid SCHEMBL8496713 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL3390328 | 0.98 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL3392313 | 0.98 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| Fingolimod SCHEMBL7445 | 0.98 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL3393539 | 0.98 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL18904548 | 0.98 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL3394797 | 0.98 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1746 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | UNIV COLUMBIA (US) | 2025-12-18 | — | — | US | claimed |
| US-12472223-B2 | Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD154 interaction | OP-T LLC (US) | 2025-11-18 | — | — | US | claimed |
| US-12227500-B2 | Substituted pyrrolo[2,3-b]pyridines for suppressing toxic endoplasmic reticulum stress | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-02-18 | — | — | US | claimed |
| CN-119451681-A | Medicament containing vitamin D derivative or pharmaceutically acceptable salt or solvate thereof for use in combination with immunomodulatory substance | 帝人制药株式会社 | 2025-02-14 | — | — | CN | claimed |
| EP-4499143-A1 | TARGETING IMMUNE INFILTRATION TO THE CENTRAL NERVOUS SYSTEM (CNS) | Ramot at Tel-Aviv University Ltd. (IL) | 2025-02-05 | — | — | EP | claimed |
| WO-2024249914-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DYSTONIA | DUKE UNIVERSITY (US) | 2024-12-05 | — | — | WO | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| WO-2024229174-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2024-11-07 | — | — | WO | claimed |
| CN-118873695-A | Diagnosis and treatment integrated targeted ultrasonic blasting nano bubble and preparation method and application thereof | 广州医科大学附属第二医院 | 2024-11-01 | — | — | CN | claimed |
| WO-2004037195-A2 | TREATMENT OF DIABETES | WARATAH PHARMACEUTICALS, INC. (CA) | 2004-05-06 | — | — | WO | claimed |
| US-20040023885-A1 | Compositions and methods for treating diabetes | BRAND STEPHEN J | 2004-02-05 | — | — | US | claimed |
| WO-2003103701-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES | WARATAH PHARMACEUTICALS, INC. (CA) | 2003-12-18 | — | — | WO | claimed |
| US-20020102279-A1 | COMPOSITIONS AND METHODS OF USING COMPOSITIONS WITH ACCELERATED LYMPHOCYTE HOMING IMMUNOSUPPRESSIVE PROPERTIES | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-01 | — | — | US | claimed |
| US-6277888-B1 | PHARMACEUTICAL COMPOSITION COMPRISING FINGOLIMOD OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF AS ACTIVE INGREDIENT AND LECITHIN | WELFIDE CORPORATION (JP) | 2001-08-21 | — | — | US | claimed |
| EP-0990440-A1 | DRUG COMPOSITION | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-04-05 | — | — | EP | claimed |
| US-6004565-A | Administering fingolimod hydrochloride | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-12-21 | — | — | US | claimed |
| US-5952316-A | FOR TREATING AUTOIMMUNE DISEASES, E.G., RHEUMATIOD ARTHRITIS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-09-14 | — | — | US | claimed |
| EP-0627406-B1 | 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT | YOSHITOMI PHARMACEUTICAL (JP) | 1998-10-28 | — | — | EP | claimed |
| US-5604229-A | 2-amino-1,3-propanediol compound and immunosuppressant | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-02-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12227500-B2 | Substituted pyrrolo[2,3-b]pyridines for suppressing toxic endoplasmic reticulum stress | HSPA5, ATP2A1, DNAJC10 | S1PR1 1472/4885S1PR3 1105/4885S1PR4 1965/4885 |
| US-20020102279-A1 | COMPOSITIONS AND METHODS OF USING COMPOSITIONS WITH ACCELERATED LYMPHOCYTE HOMING IMMUNOSUPPRESSIVE PROPERTIES | CD47, S1PR5, S1PR3 | S1PR1 7/4885S1PR3 3/4885S1PR4 5/4885 |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | HSPA5, ATP2A1, DNAJC10 | S1PR1 1472/4885S1PR3 1105/4885S1PR4 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.